Ceyhun VARIM, Taner DEMİRCİ, Hasret CENGİZ, Sedat ÇETİN

The role and importance of auxiliary tests in differential diagnosis in patients with mildly high basal 17-OH-progesterone levels in the evaluation of hirsutism

Background/aim: In the differential diagnosis of hirsutism, early follicular basal 17-OH-progesterone levels sometimes overlap with the diagnosis of late onset congenital adrenal hyperplasia (LOCAH) and other causes of hyperandrogenism. This study aims to investigate the role of some common tests and clinical findings in differential diagnosis in such cases. Materials and methods: One hundred seventy-five female patients with hirsutism and mildly high initial 17-OH-progesterone levels (2-10 ng/mL) were included in the study. The cases were divided into three groups according to their diagnosis: LOCAH (n = 16, mean age = 26.1 ± 6.9), polycystic ovary syndrome (PCOS) (n = 122, mean age = 23.9 ± 5.1), and intracranial hypertension (IH) (n = 37, mean age = 25.2 ± 7.3). Clinical signs and symptoms, such as menstrual irregularity and hirsutism score, and hormone levels including total testosterone and dehydroepiandrosterone sulfate (DHEAS), were compared between the groups. Results: There was no difference between the groups with PCOS, LOCAH, and IH for total testosterone level results (P = 0.461). The DHEAS level was higher in the PCOS group than in the LOCAH group (449.6 ± 151.14 vs. 360.31 ± 152.40, P = 0.044). While there was no difference between the PCOS and LOCAH groups in terms of menstrual irregularity (P = 0.316), the hirsutism score for IH was significantly lower than those of PCOS and LOCAH (9.2 vs. 12.2 and 11.1, respectively; P < 0.001). Basal 17-OH-progesterone levels were higher in the LOCAH group than in the other groups (P = 0.016). Conclusion: While DHEAS level was lower in LOCAH than in PCOS, it was not different from that in IH. While the severity of hirsutism was higher in LOCAH than in IH, it was not different from that in PCOS. Menstrual irregularity was similar between PCOS and LOCAH. According to these results, although the auxiliary tests and clinical findings for the diagnosis of LOCAH contribute to the clinical interpretation, they are not superior to the 17-OH-progesterone level for diagnosis.

PDF

___

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR et al. Prevalence of the Polycystic Ovary Syndrome in unselected black and white women of the southeastern United States: a prospective study 1. The Journal of Clinical Endocrinology & Metabolism 1998; 83(9):3078-3082.doi: 10.1210/jcem.83.9.5090
2. Lipton MG, Sherr L, Elford J, Rustin MHA, Clayton WJ. Women living with facial hair: the psychological and behavioral burden. Journal of Psychosomatic Research 2006; 61(2):161- 168.doi: 10.1016/j.jpsychores.2006.01.016
3. Hahn S, Janssen OE, Tan S, Pleger K, Mann K et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. European Journal of Endocrinology 2005; 153(6):853-860.doi: 10.1530/eje.1.02024
4. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. The Journal of Clinical Endocrinology and Metabolism 1961; 21:1440-1447.doi: 10.1210/jcem-21-11- 1440
5. Rosenfield RL. Clinical practice. Hirsutism. The New England Journal of Medicine 2005; 353(24):2578-2588.doi: 10.1056/ NEJMcp033496
6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reproduction 2004; 19: 41-47.doi: 10.1093/ humrep/deh098
7. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J et al. Androgen excess in women: experience with over 1000 consecutive patients. Journal of Clinical Endocrinology and Metabolism 2004; 89: 453-462.doi: 10.1210/jc.2003-031122
8. Carmina E, Rosato F, Jannì A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. The Journal of Clinical Endocrinology and Metabolism 2006; 91(1):2-6.doi: 10.1210/jc.2005-1457
9. Azziz R, Dewailly D, Owerbach D. Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. The Journal of Clinical Endocrinology and Metabolism 1994; 78(4):810- 815.doi: 10.1210/jcem.78.4.8157702
10. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine Reviews 2000; 21(3):245-291.doi: 10.1210/edrv.21.3.0398
11. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. The Journal of Clinical Endocrinology and Metabolism 1983; 57(2):320-326.doi: 10.1210/jcem-57-2-320
12. Speiser PW, White PC. Congenital adrenal hyperplasia. The New England Journal of Medicine 2003; 349(8):776-788.doi: 10.1056/NEJMra021561
13. Wilson RC, Mercado AB, Cheng KC, New MI. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. The Journal of Clinical Endocrinology and Metabolism 1995; 80(8): 2322-2329.doi: 10.1210/jcem.80.8.7629224
14. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH et al. Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism 2013; 98(12):4565-4592.doi: 10.1210/jc.2013-2350
15. Kamel N, Tonyukuk V, Emral R, Corapçioǧlu D, Baştemir M et al. The prevalence of late onset congenital adrenal hyperplasia in hirsute women from Central Anatolia. Endocrine Journal 2003; 50(6):815-823.doi: 10.1507/endocrj.50.815
16. Lobo RA, Goebelsmann U. Adult manifestation of congenital adrenal hyperplasia due to incomplete 21-hydroxylase deficiency mimicking polycystic ovarian disease. American Journal of Obstetrics and Gynecology 1980; 138(6):720-726. doi: 10.1016/0002-9378(80)90095-2
17. New MI. Nonclassical congenital adrenal hyperplasia and the polycystic ovarian syndrome. Annals of the New York Academy of Sciences 1993; 687(1):193-205.doi: 10.1111/ j.1749-6632.1993.tb43866.x
18. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. American Journal of Human Genetics 1985; 37(4):650-667.
19. The VL, Lachance Y, Labrie C, Leblanc G, Thomas JL et al. Full length cdna structure and deduced amino acid sequence of human 3β-hydroxy-5-ene steroid dehydrogenase. Molecular Endocrinology 1989; 3(8):1310-1312.doi: 10.1210/mend-3-8- 1310
20. Peter M, Dubuis JM, Sippell WG. Disorders of the aldosterone synthase and steroid 11β-hydroxylase deficiencies. Hormone Research 1999; 51:211-222.doi: 10.1159/000023374
21. Meikle AW. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Yearbook of Endocrinology 2011; 2011:283-284.doi: 10.1016/s0084-3741(10)79621-9
22. Moore A, Magee F, Cunningham S, Culliton M, Mckenna TJ. Adrenal abnormalities in idiopathic hirsutism. Clinical Endocrinology 1983;18(4):391-399. doi: 10.1111/j.1365- 2265.1983.tb00584.x
23. Goodarzi MO, Carmina E, Azziz R. DHEA, DHEAS and PCOS. Journal of Steroid Biochemistry and Molecular Biology 2015; 145: 213-225.doi: 10.1016/j.jsbmb.2014.06.003
24. Pall M, Azziz R, Beires J, Pignatelli D. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertility and Sterility 2010;94(2):684-689.doi: 10.1016/j. fertnstert.2009.06.025
25. Dharia S, Slane A, Jian M, Conner M, Conley AJ et al. Effects of aging on cytochrome B5 expression in the human adrenal gland. Journal of Clinical Endocrinology and Metabolism 2005; 90(7):4357-4361.doi: 10.1210/jc.2005-0017